Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV stabilized DT-preF
- Development stage
- Preclinical
- Lead developer
- Calder Biosciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RSV stabilized DT-preF (also known as DT-preF) is a preclinical-stage recombinant protein subunit vaccine being developed by Calder Biosciences for the prevention of respiratory syncytial virus (RSV) infections, particularly in older adults and maternal/infant populations. The vaccine utilizes Calder's proprietary 3D-Vaxlock dityrosine-crosslinking technology to introduce site-specific, covalent dityrosine bonds that lock the RSV fusion (F) glycoprotein in its highly immunogenic prefusion conformation (preF). This stabilization prevents the F protein from transitioning to its poorly protective postfusion state, thereby exposing key neutralizing epitopes (such as Site Ø and the Site IV/V interface). Preclinical studies have demonstrated that DT-preF elicits significantly higher neutralizing antibody titers compared to traditionally stabilized preF antigens (such as DS-Cav1) and can overcome immunosenescence in aged animal models when formulated with an alum adjuvant.
- Other names
- RSV DT-PreF VaccineRSV Stabilized DT-preF
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV stabilized DT-preF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV stabilized DT-preF.